13 results about "Alprazolam" patented technology

The invention relates to the field of epilepsy, in particular to application of alprazolam gel particles in preparation of a medicine for treating the state of epilepsy. The invention provides application of alprazolam gel particles in preparation of a medicine for treating and / or preventing epileptic seizure of a subject, and is characterized in that the alprazolam gel particles are prepared by the following steps: S101, dropwise adding an alprazolam solution into a first solution to form an internal phase solution; s102, forming a preliminarily cured pre-crosslinked liquid drop; s103, forming cured particles; and S104, obtaining the alprazolam gel particles. The blood brain barrier transmittance of the alprazolam gel particles provided by the invention can reach 1.5-2 times that of the prior art, and the alprazolam gel particles are high in effect taking speed, have dual properties of quick release and continuous release, and are suitable for effective and timely treatment of epileptic seizure patients.

The invention relates to an alprazolam oral solid composition and a preparation method thereof. In one aspect, the invention relates to an alprazolam tablet, which is prepared by preparing premixed particles containing alprazolam in advance and then preparing the tablet by a wet granulation and tabletting method. The premixed particles comprise alprazolam, microcrystalline cellulose and the like, and the tablet further comprises microcrystalline cellulose, corn starch, silicon dioxide, magnesium stearate and the like. The alprazolam tablet disclosed by the invention can be used as a medicine for resisting anxiety, tension, depression, excitation, hypnosis, panic, relieving acute alcohol withdrawal symptoms and resisting drug-induced intractable hiccup, and has certain excellent performance.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to a detection method of alprazolam related substances, the detection method adopts high performance liquid chromatography, and the chromatographic conditions are as follows: a mobile phase A and a mobile phase B are adopted as mixed mobile phases for gradient elution; wherein the mobile phase A is a methanol-ammonium acetate solution or an acetonitrile-ammonium acetate solution, and the mobile phase B is a mixed solution of methanol and / or acetonitrile and an ammonium acetate solution, the detection method provided by the invention has the advantages that the detected impurities are more, the retention ability of main components and each impurity in the mobile phase system is stronger, the peak response is higher, each compound can be effectively separated, and the detection accuracy is high. And related substances in alprazolam can be well monitored.

The invention discloses an alprazolam nasal spray and a preparation method thereof, and provides the alprazolam nasal spray which is good in stability, small in irritation, convenient, quick to take effect and extremely small in side effect, so that the medication compliance of a patient and the convenience of clinical medication are improved, and the preparation process is simple to operate, safe, environment-friendly and suitable for industrial mass production.

Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

The invention relates to a detection method and application of an illegal additive cyclopropyl flualprazolam, and the detection method comprises the following steps: 1) adding methanol into a sample to be detected, extracting, centrifuging, and taking supernate for detection; (2) preparing a standard working solution from the standard substance cyclopropyl flualprazolam for qualitative detection or / and making of a standard curve; (3) respectively detecting the treated to-be-detected sample solution and the treated standard working solution by using a liquid chromatography-tandem mass spectrometry method; and 4) according to the obtained chromatogram of the standard working solution, correspondingly judging and detecting the chromatogram of the to-be-detected sample solution so as to obtain qualitative and quantitative results of the cyclopropyl flualprazolam in the to-be-detected sample. The method comprises the following steps: adding a to-be-detected sample into methanol for ultrasonic extraction, effectively dissolving the to-be-detected illegal additive into a to-be-detected solution, performing chromatographic column separation, and performing qualitative and quantitative analysis according to a liquid chromatograph-mass spectrometer. And optimization and methodological verification are carried out on different food matrix pretreatment methods, so that the quantitative accuracy of the method is ensured.

Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

The invention discloses an application of andrographolide in preparation of a medicine for preventing and / or treating benzodiazepine # imgabs0 # medicine addiction. The research finds that different doses of andrographolide can obviously prevent the formation of mouse CPP (Chlorinated Polymorphism) induced by a benzene dinitrogen # imgabs 1 # medicine namely flualprazolam and alprazolam; different doses of andrographolide can also significantly improve the withdrawal symptoms of benzene dinitrogen # imgabs2 # medicines including flualprazolam, flubrozolam and alprazolam, and do not affect the spontaneous movement ability of mice. Therefore, the andrographolide can be used for preparing the medicine for preventing and / or treating the benzodiazepine # imgabs3 # medicine addiction.

The present invention discloses a method for preparing alprazolam and its impurity LAP. The method uses 7-chloro-5-phenylbenzodiazepine as a starting material, undergoes an acylation reaction with acetyl chloride, and then undergoes a cyclization reaction with hydrazine hydrate to obtain an alprazolam finished product. The method can avoid the production of impurity LAP, while avoiding the use of phosphorus pentasulfide and the risk of poisoning caused by the generation of hydrogen sulfide during the reaction, thereby greatly improving the safety of the process. The present invention uses 7-chloro-5-phenylbenzodiazepine as a starting material, reacts with chloroacetic acid, and then undergoes a cyclization reaction with hydrazine hydrate under the catalysis of a condensing agent N,N'-carbonylbis(1,2,4-triazole) to obtain the impurity LAP. The method can be widely used in the quality research of alprazolam raw materials and their preparations, thereby improving the safety, effectiveness and quality controllability of the drug. #imgabs0#

Alprazolam formulated as an inhaled condensation aerosol and method for treating epilepsy and / or seizures.

The application discloses a preparation method of small-granularity alprazolam crystal form I and belongs to the technical field of crystal preparation. Coarse alprazolam is dissolved in an alcohol solvent, and stirring and dissolving are carried out at 60-90 DEG C to obtain an alprazolam solution, and insoluble substances are removed by filtration; crystal seeds are added into water at 15-30 DEG C; the alprazolam solution is added into the water containing the crystal seeds, the temperature is controlled to be 15-30 DEG C, and ultrasonic treatment is carried out by introducing ultrasonic waves; the system is cooled to 0-5 DEG C, and the constant temperature is maintained for 1-3 h for crystal growth; and filtration, washing and drying are carried out to obtain the small-granularity alprazolam crystal form I. The prepared alprazolam realizes the preparation of the small-granularity alprazolam crystal form I on the basis of not changing the medicinal crystal form of the alprazolam, the particle size distribution is uniform, and the solubility is better; and the preparation method is simple, reproducible and easy for industrial production.

A pharmaceutical composition comprising ebastine and alprazolam is disclosed. Also disclosed is a method of using the pharmaceutical composition for treating a patient suffering from insomnia.

Disclosed is a pharmaceutical composition comprising ebastine and alprazolam. Also disclosed is a method of using a pharmaceutical composition for treating a patient suffering from insomnia.